| |  Online-Ressource |
|---|
| Verfasst von: | Lübke, Johannes [VerfasserIn]  |
|---|
| | Naumann, Nicole [VerfasserIn] |
|---|
| | Metzgeroth, Georgia [VerfasserIn] |
|---|
| | Kreil, Sebastian [VerfasserIn] |
|---|
| | Brand, Timo [VerfasserIn] |
|---|
| | Horny, Hans-Peter [VerfasserIn] |
|---|
| | Sotlar, Karl [VerfasserIn] |
|---|
| | Cross, Nicholas C. P. [VerfasserIn] |
|---|
| | Fabarius, Alice [VerfasserIn] |
|---|
| | Valent, Peter [VerfasserIn] |
|---|
| | Hofmann, Wolf-Karsten [VerfasserIn] |
|---|
| | Reiter, Andreas [VerfasserIn] |
|---|
| | Schwaab, Juliana [VerfasserIn] |
|---|
| Titel: | Response and resistance to cladribine in patients with advanced systemic mastocytosis |
|---|
| Titelzusatz: | a registry-based analysis: original article |
|---|
| Verf.angabe: | Johannes Lübke, Nicole Naumann, Georgia Metzgeroth, Sebastian Kreil, Timo Brand, Hans-Peter Horny, Karl Sotlar, Nicholas C.P. Cross, Alice Fabarius, Peter Valent, Wolf-Karsten Hofmann, Andreas Reiter, Juliana Schwaab |
|---|
| E-Jahr: | 2023 |
|---|
| Jahr: | August 2023 |
|---|
| Umfang: | 9 S. |
|---|
| Illustrationen: | Illustrationen |
|---|
| Fussnoten: | Online verfügbar: 4. April 2023 ; Gesehen am 03.04.2024 |
|---|
| Titel Quelle: | Enthalten in: Annals of hematology |
|---|
| Ort Quelle: | Berlin : Springer, 1991 |
|---|
| Jahr Quelle: | 2023 |
|---|
| Band/Heft Quelle: | 102(2023), 8 vom: Aug., Seite 2077-2085 |
|---|
| ISSN Quelle: | 1432-0584 |
|---|
| Abstract: | We sought to evaluate the efficacy of the purine analogue cladribine in 79 patients with advanced systemic mastocytosis (AdvSM) using data from the ‘German Registry on Disorders of Eosinophils and Mast Cells (GREM)’. The overall response rate according to modified Valent criteria (46 evaluable patients) for first- (1L) and second-line (2L) cladribine treatment was 41% (12/29) and 35% (6/17, P = 0.690), respectively, and the median overall survival (OS, all patients evaluable) was 1.9 years (n = 48) and 1.2 years (n = 31; P = 0.311). Univariate and multivariable analyses of baseline and on-treatment parameters identified diagnosis of mast cell leukemia (hazard ratio [HR] 3.5, 95% confidence interval [CI, 1.3-9.1], P = 0.012), eosinophilia ≥ 1.5 × 109/L (HR 2.9 [CI 1.4-6.2], P = 0.006) and < 3 cycles of cladribine (HR 0.4 [CI 0.2-0.8], P = 0.008) as independent adverse prognostic parameters for OS. There was no impact of other laboratory (anemia, thrombocytopenia, serum tryptase) or genetic markers (mutations in SRSF2, ASXL1 or RUNX1) on OS. In consequence, none of the recently established prognostic scoring systems (MARS, IPSM, MAPS or GPSM) was predictive for OS. Modified Valent criteria were superior to a single factor-based response assessment (HR 2.9 [CI 1.3-6.6], P = 0.026). In conclusion, cladribine is effective in 1L and 2L treatment of AdvSM. Mast cell leukemia, eosinophilia, application of < 3 cycles and a lack of response are adverse prognostic markers. |
|---|
| DOI: | doi:10.1007/s00277-023-05180-y |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
kostenfrei: Volltext: https://doi.org/10.1007/s00277-023-05180-y |
|---|
| | kostenfrei: Volltext: https://link.springer.com/article/10.1007/s00277-023-05180-y |
|---|
| | DOI: https://doi.org/10.1007/s00277-023-05180-y |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Advanced systemic mastocytosis |
|---|
| | Chemotherapy |
|---|
| | Cladribine |
|---|
| | Purine analogue |
|---|
| K10plus-PPN: | 1884937934 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Response and resistance to cladribine in patients with advanced systemic mastocytosis / Lübke, Johannes [VerfasserIn]; August 2023 (Online-Ressource)
